Press Releases
ThinkEquity LLC acts as Co-Manager on NPS Pharmaceuticals, Inc.'s Public Offering of Common Stock
SAN FRANCISCO, April 21, 2011 — ThinkEquity LLC — A Panmure Gordon Company, a leading investment banking boutique focused on growth companies and their investors, is pleased to announce the completion of a public offering of stock for NPS Pharmaceuticals, Inc. on April 19, 2011.
The Company issued 12,650,000 shares of common stock at a price of $9.00 per share raising gross proceeds of approximately $114 million. As part of this offering, the underwriters exercised in full their option to purchase an additional 1,650,000 shares of common stock from the Company. ThinkEquity LLC acted as Co-Manager in this transaction. NPS Pharmaceuticals' common stock trades on the NASDAQ Global Market under the symbol "NPSP".
NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The Company is advancing two Phase 3 registration programs, GATTEX® (teduglutide) in short bowel syndrome (SBS) and NPSP558 (parathyroid hormone (1-84) [rDNA origin] injection) in hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.
The securities described above were offered by NPS Pharmaceuticals, Inc. pursuant to a shelf registration statement and prospectus supplement filed with and declared effective by the Securities and Exchange Commission. The final prospectus is available at the SEC's website at www.sec.gov, or by contacting ThinkEquity LLC at 600 Montgomery Street, 3rd Floor, San Francisco, CA 94111, Attn: Prospectus Department (415) 249-2935.
ThinkEquity Contact:
Janet Faleski, ThinkEquity
Managing Director
T: (212) 468-7083
E: jfaleski@thinkequity.com
Media Inquiries:
Nathaniel Webb, Panmure Gordon
Group Communications and Investor Relations Director
T: +44 20 7614 8333
E: nathaniel.webb@panmure.com
About ThinkEquity LLC — A Panmure Gordon Company
Focused on the growth sectors of the economy, ThinkEquity provides research, equity financing, M&A advisory, institutional sales and trading, wealth management and asset management services to institutional investors, corporate and private clients, venture capitalists, entrepreneurs and financial sponsors. As a Panmure Gordon company, ThinkEquity accesses the combined financial expertise of professionals based in San Francisco, New York, Boston, Chicago, London, Liverpool and Geneva. Research-driven, we remain true to our founding principles: the power of growth, focus, deep domain expertise and people. www.thinkequity.com
About the Panmure Gordon Group
Founded in 1876, Panmure Gordon & Co. (PMR.L) is a leading independent institutional stockbroker and investment bank. Encompassing its US franchise, ThinkEquity, LLC, the Group employs approximately 240 professionals across the US, the UK, Singapore and Nyon, Switzerland, offering a blend of transatlantic financial services including research, sales and trading, wealth management and asset management. www.panmure.com